Mental health apps improve motivation, confidence in users

Researchers from Brigham Young University have found mental health mobile applications to be feasible self-help tools to improve mental or emotional health, according to a study published in JMIR mHealth.

Mobile health apps have increased in numbers as mHealth becomes more routine, but evidence into whether these apps are feasible in improving mental health is lacking. In this study, researchers examined the correlations between theoretical behavior change mechanisms and the utilization of mental health apps.

"These apps are engaging and if we can get people to use them more often, the potential certainly exists to help people change their behavior," said co-author Josh West.

The study enrolled 150 participants who used mental or emotional health apps in the last six months. Participants were asked to complete a survey on app engagement, likeability and behavioral changes. Results showed that participants reported the app increased motivation, desire to set goals, confidence, control and intentions to be mentally and emotionally healthy.

"Our findings show that mental and emotional health focused apps have the ability to positively change behavior," said Ben Crookston, associate professor of health science at BYU. "This is great news for people looking for inexpensive, easily accessible resources to help combat mental and emotional health illness and challenges."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.